Stroke is a leading cause of death and disability worldwide. Stem cell therapy is an emerging therapeutic modality with evidence of significant benefits in preclinical stroke models. A number of phase I and II clinical trials have now been completed, with several more currently under way. Translation to the bedside, however, remains a long way off, and there are many questions that remain unanswered. This review will summarize the current evidence and ongoing clinical trials worldwide, and explore the challenges to making this a realistic treatment option for the future. © 2012 Banerjee et al, publisher and licensee Dove Medical Press Ltd.
CITATION STYLE
Banerjee, S., Williamson, D. A., Habib, N., & Chataway, J. (2012). The potential benefit of stem cell therapy after stroke: An update. Vascular Health and Risk Management, 8(1), 569–580. https://doi.org/10.2147/VHRM.S25745
Mendeley helps you to discover research relevant for your work.